4Filed Jun 3, 8:00 PM ET

U S Global Investors (GROW) Control Person Derek Pilecki Buys Shares

$GROW · U S GLOBAL INVESTORS INC

Research Summary

AI-generated summary of this SEC filing

Updated

U S Global Investors (GROW) Control Person Derek Pilecki Buys Shares

What Happened
Derek Steven Pilecki, listed as a Control Person, purchased a total of 20,826 shares of U S Global Investors, Inc. (GROW) in two open-market transactions: 20,496 shares at $2.59 on 2026-06-02 (≈ $53,177) and 330 shares at $2.60 on 2026-06-03 (≈ $858), for a combined cost of about $54,035. These were purchases (buying stock), which are typically viewed as a more informative/positive signal than routine sales, though no motive is stated.

Key Details

  • Transaction dates and prices: 2026-06-02 — 20,496 shares @ $2.59; 2026-06-03 — 330 shares @ $2.60. Reported price is a weighted average.
  • Total shares acquired: 20,826; total cash outlay: ≈ $54,035.
  • Shares owned after transaction: aggregate beneficial ownership reported as 1,121,593 shares across accounts. Breakdown: Gator Financial Partners, LLC — 937,228; Gator Qualified Partners, LLC — 102,000; ECA Fund, LP — 76,365; Managed Account — 6,000.
  • Footnotes: Purchases were made in managed accounts (Gator Financial Partners, LLC and ECA Fund, LP) where Gator Capital Management, LLC exercises investment discretion. Gator Capital Management disclaims beneficial ownership except for its pecuniary interest. The filing notes the price is a weighted average and full per-price detail is available on request.
  • Timeliness: Form 4 filed 2026-06-04 for transactions on 06-02 and 06-03 — appears timely (within required reporting window).

Context
These were straightforward open-market purchases by an insider/control person and not option exercises, awards, or gifts. The shares were bought through investment vehicles managed by Gator Capital Management; the manager disclaims beneficial ownership aside from economic interest. Purchases by insiders can be meaningful to investors, but they do not alone prove future performance—use alongside other research.